vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Madison Square Garden Entertainment Corp. (MSGE). Click either name above to swap in a different company.
Madison Square Garden Entertainment Corp. is the larger business by last-quarter revenue ($424.8M vs $281.3M, roughly 1.5× Guardant Health, Inc.). Madison Square Garden Entertainment Corp. runs the higher net margin — 21.8% vs -45.7%, a 67.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 12.5%). Over the past eight quarters, Madison Square Garden Entertainment Corp.'s revenue compounded faster (48.9% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Madison Square Garden Sports Corp. is an American sports holding company based in New York City.
GH vs MSGE — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $424.8M |
| Net Profit | $-128.5M | $92.7M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 38.6% |
| Net Margin | -45.7% | 21.8% |
| Revenue YoY | 39.4% | 12.5% |
| Net Profit YoY | -15.8% | 22.2% |
| EPS (diluted) | $-1.01 | $1.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $424.8M | ||
| Q3 25 | $265.2M | $154.1M | ||
| Q2 25 | $232.1M | $145.1M | ||
| Q1 25 | $203.5M | $206.0M | ||
| Q4 24 | $201.8M | $377.6M | ||
| Q3 24 | $191.5M | $134.1M | ||
| Q2 24 | $177.2M | $177.6M | ||
| Q1 24 | $168.5M | $191.6M |
| Q4 25 | $-128.5M | $92.7M | ||
| Q3 25 | $-92.7M | $-21.7M | ||
| Q2 25 | $-99.9M | $-27.2M | ||
| Q1 25 | $-95.2M | $8.0M | ||
| Q4 24 | $-111.0M | $75.9M | ||
| Q3 24 | $-107.8M | $-19.3M | ||
| Q2 24 | $-102.6M | $66.9M | ||
| Q1 24 | $-115.0M | $2.8M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 38.6% | ||
| Q3 25 | -37.3% | -19.3% | ||
| Q2 25 | -45.9% | -17.7% | ||
| Q1 25 | -54.6% | 13.3% | ||
| Q4 24 | -62.4% | 36.8% | ||
| Q3 24 | -61.3% | -13.8% | ||
| Q2 24 | -56.8% | -5.0% | ||
| Q1 24 | -59.2% | 8.8% |
| Q4 25 | -45.7% | 21.8% | ||
| Q3 25 | -35.0% | -14.0% | ||
| Q2 25 | -43.0% | -18.7% | ||
| Q1 25 | -46.8% | 3.9% | ||
| Q4 24 | -55.0% | 20.1% | ||
| Q3 24 | -56.3% | -14.4% | ||
| Q2 24 | -57.9% | 37.7% | ||
| Q1 24 | -68.2% | 1.5% |
| Q4 25 | $-1.01 | $1.94 | ||
| Q3 25 | $-0.74 | $-0.46 | ||
| Q2 25 | $-0.80 | $-0.56 | ||
| Q1 25 | $-0.77 | $0.17 | ||
| Q4 24 | $-0.90 | $1.56 | ||
| Q3 24 | $-0.88 | $-0.40 | ||
| Q2 24 | $-0.84 | $1.32 | ||
| Q1 24 | $-0.94 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $157.1M |
| Total DebtLower is stronger | $1.5B | $554.6M |
| Stockholders' EquityBook value | $-99.3M | $36.0M |
| Total Assets | $2.0B | $1.8B |
| Debt / EquityLower = less leverage | — | 15.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $157.1M | ||
| Q3 25 | $580.0M | $29.9M | ||
| Q2 25 | $629.1M | $43.0M | ||
| Q1 25 | $698.6M | $89.0M | ||
| Q4 24 | $525.5M | $54.9M | ||
| Q3 24 | $585.0M | $37.3M | ||
| Q2 24 | $933.7M | $33.3M | ||
| Q1 24 | $1.0B | $28.0M |
| Q4 25 | $1.5B | $554.6M | ||
| Q3 25 | $1.1B | $581.7M | ||
| Q2 25 | $1.1B | $568.8M | ||
| Q1 25 | $1.1B | $577.4M | ||
| Q4 24 | $1.1B | $584.7M | ||
| Q3 24 | — | $647.0M | ||
| Q2 24 | — | $599.2M | ||
| Q1 24 | — | $602.5M |
| Q4 25 | $-99.3M | $36.0M | ||
| Q3 25 | $-354.5M | $-65.8M | ||
| Q2 25 | $-305.5M | $-13.3M | ||
| Q1 25 | $-250.8M | $9.5M | ||
| Q4 24 | $-139.6M | $10.3M | ||
| Q3 24 | $-60.1M | $-48.7M | ||
| Q2 24 | $-1.6M | $-23.2M | ||
| Q1 24 | $68.3M | $-94.6M |
| Q4 25 | $2.0B | $1.8B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.3B | $1.7B | ||
| Q1 25 | $1.3B | $1.7B | ||
| Q4 24 | $1.5B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.6B | $1.6B | ||
| Q1 24 | $1.7B | $1.5B |
| Q4 25 | — | 15.40× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 60.61× | ||
| Q4 24 | — | 56.61× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $164.4M |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | 1.77× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $164.4M | ||
| Q3 25 | $-35.4M | $19.8M | ||
| Q2 25 | $-60.3M | $-27.0M | ||
| Q1 25 | $-62.7M | $56.8M | ||
| Q4 24 | $-64.5M | $112.9M | ||
| Q3 24 | $-51.1M | $-27.4M | ||
| Q2 24 | $-94.0M | $212.0K | ||
| Q1 24 | $-30.3M | $5.8M |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | — | 1.77× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.07× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 2.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
MSGE
| Ticketing And Venue License Fee Revenues | $263.5M | 62% |
| Food Beverage And Merchandise Revenues | $64.3M | 15% |
| Related Party | $43.9M | 10% |
| Arena Licensing Fees And Other Leasing Revenue | $35.2M | 8% |
| Other | $15.9M | 4% |
